Grants for County governments - Federal

This funding opportunity provides financial support for state and local governments, educational institutions, nonprofits, and tribal organizations to advance plant conservation and restoration projects in Colorado, focusing on biodiversity and climate resilience.

This notice of funding opportunity (NOFO) invites applications for REsearch Across Complementary and Integrative Health Institutions (REACH) virtual resource centers. REACH virtual resource centers will foster institutional partnerships and provide resources to support research activities and research training for faculty who work at accredited complementary and integrative health clinical institutions, such as: Schools of acupuncture, chiropractic, osteopathy, naturopathy, physical therapy, and music and art therapy. The REACH virtual resource centers will provide a variety of services and resources including, but not limited to Administrative Support, Research Support, Grantsmanship, Mentoring and Training, and Team Building to support clinician scientists located at complementary and integrative health clinical institutions to form multi and interdisciplinary research teams and pursue externally funded research aligned with NCCIH Strategic Priorities for symptom management. REACH centers should focus on resources to support investigators pursuing clinical research (e.g., observational, epidemiological, mechanistic clinical research, mixed methods, feasibility studies, etc). It is expected that REACH virtual resource centers will (1) improve the quality and quantity of federal research grant applications submitted by clinician scientist faculty at complementary and integrative health clinical institutions; (2) aid the formation of multi and interdisciplinary research partnerships across partnering complementary and integrative health clinical institutions; (3) help to enhance the research environment at complementary and integrative health clinical institutions; and (4) support a pipeline for clinician scientists trained in complementary and integrative health practices to pursue research careers at clinical institutions.

The purpose of this funding opportunity announcement (FOA) is to support efficient natural history studies alone or in conjunction with the development and validation of clinical outcome assessments (COAs) and/or biomarker studies to address the unmet needs in rare neurodegenerative diseases for children and adults. Through the support of studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare neurodegenerative disease or multiple rare neurodegenerative diseases with similar pathophysiology, and facilitate rare disease product development.

This funding opportunity provides financial assistance to state, Tribal, and local governments in EPA Region 3 to develop and improve wetland protection programs that enhance wetland health and increase wetland areas.

This funding opportunity provides financial support to research centers focused on improving interventions and services for children and adolescents with autism and developmental disabilities across the United States.

This funding opportunity supports early-stage research aimed at improving understanding and treatment of rare autoimmune neuropathies affecting the peripheral nervous system, specifically targeting innovative approaches to disease mechanisms, biomarkers, and therapies.

This funding opportunity provides financial support for organizations to operate a national hotline that assists victims of human trafficking by offering emergency help, information, and referrals across the United States.

This funding opportunity supports innovative bioengineering projects that aim to improve healthcare solutions and research methods, particularly in terms of effectiveness, efficiency, and accessibility.

This grant provides funding to state and local governments to conduct DNA testing and improve evidence preservation in violent felony cases, helping to address wrongful convictions and support justice.

The "Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH)" grant is designed to fund research programs that aim to improve the prevention, early detection, diagnosis, and treatment of cancer in underserved and/or underrepresented populations, with a focus on translating research findings into real-world applications.

Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services aims to fund research that develops and tests innovative models of integrated healthcare to improve outcomes for individuals at high risk for or living with HIV, Hepatitis, and substance use disorders by enhancing service delivery and coordination of care.

This funding opportunity provides financial support to community coalitions that have previously received DFC grants, enabling them to implement strategies to prevent and reduce substance use among youth.

This grant provides funding to colleges and universities to enhance research training for undergraduate students, particularly those from underrepresented groups, in order to prepare them for advanced degrees in biomedical research.

The purpose of this program is to recruit and retain outstanding, postdoctoral-level health professionals who have demonstrated potential and interest in pursuing careers as clinician-investigators. To address the growing need for this critical component of the research workforce, this funding opportunity seeks applications from institutional programs that can provide outstanding mentored research opportunities for Resident-Investigators and foster their ability to transition to individual career development research awards. The program will support institutions to provide support for up to 2 years of research conducted by Resident-Investigators in structured programs for clinician-investigators with defined program milestones. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

The Good Neighbor Authority (GNA) fosters partnerships with states, counties, and Indian tribes for planning and executing forest, rangeland, and watershed restoration. GNA allows treating infested trees, reducing hazardous fuels, and other activities benefiting forest health GNA supports diverse projects for land and habitat resilience, such as treating noxious weeds and invasive species, fuels management, community assistance, forest and rangeland restoration, wildlife habitat connectivity, NEPA compliance, riparian restoration, and targeted grazing. These activities, spanning multiple ownerships, leverage cooperation and funds for effective implementation, enhancing overall ecological outcomes.

This grant provides funding to organizations that engage AmeriCorps members in service projects addressing community needs, particularly in rural, tribal, and high-poverty areas, while focusing on priorities like youth mental health, public safety, and workforce development.

The purpose of this NOFO is to implement and evaluate PrEPmate, a mobile health (mHealth) intervention to increase HIV pre-exposure prophylaxis (PrEP) adherence and retention in PrEP care among young men who have sex with men (collectively referred to as YMSM) and transgender women of color. PrEPmate features youth-tailored interactive content, reminders (e.g., clinic appointments, prescription refills, and dosing reminders), short message service (SMS) for PrEP clinic patients and clinical providers, and a dashboard that may be integrated into electronic medical records (EMR) or as a stand-alone digital patient monitoring system. The recipient will facilitate implementation of the PrEPmate intervention at three clinical sites located in the southern region of the United States, where there is increased HIV disease burden. The recipient will monitor and evaluate how a mHealth intervention is integrated into the delivery of clinical services to improve PrEP adherence and retention in care. Evaluation will be conducted using a mixed-method approach involving EMR reviews and interviews with agency staff that implement PrEPmate. The project's primary outcomes include increased PrEP medication adherence and retention in PrEP care among patients and increased adaptability and sustainability among clinical providers. A secondary outcome will be the identification of best practices and lessons learned for implementing PrEPmate in clinics serving YMSM and transgender women of color.

This funding opportunity supports early-career scientists conducting innovative research to improve the understanding, diagnosis, treatment, or prevention of mental health disorders.

This funding opportunity provides financial support for non-profits, local governments, and tribal entities to create or improve permanent supportive housing for individuals and families experiencing homelessness, particularly those with disabilities.

The FY24 PCRP Exploration Hypothesis Development Award supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more of the FY24 PCRP Overarching Challenges. This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. Results of studies conducted through this award may provide the scientific premise upon which a new hypothesis can be based or initial proof of principle of an innovative hypothesis, laying the groundwork for future avenues of scientific investigation. Presentation of preliminary data is inconsistent with the intent of this award mechanism and is therefore strongly discouraged. However, logical reasoning and a sound scientific rationale for the proposed work must be described. Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i, Full Application Submission Type, for more information. New for FY24: Clinical research is allowed. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities. Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. The funding instrument for awards made under the program announcement will be grants (31 USC 6304). The anticipated direct costs budgeted for the entire period of performance for an FY24 Exploration Hypothesis Development Award should not exceed $150,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $3.60M to fund approximately 15 Exploration Hypothesis Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030. Research Involving Animals: All research funded by the FY24 PCRP Exploration-Hypothesis Development Award involving new and ongoing research with animals must be reviewed and approved by the USAMRDC Office of Human and Animal Research Oversight (OHARO; previously the Human Research Protection Office), Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is not required. Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies. Refer to the General Application Instructions for additional information.